The information on this part of the website is intended only for health care professionals. I am an expert within the meaning of Act No. country xy. I herewith confirm that I am a professional according to this definition.
Unfortunately, as you are not a health care professional we cannot provide you this information.
Two trials with L. reuteri Protectis (BioGaia) have shown positive effects on prevention of infectious disease: Supplementation with BioGaia has a significantly positive effect on the incidence of common infections in children in day care and improve work-place healthiness by reducing short term sick-leave caused by respiratory or gastrointestinal infections.
Interacts with the immune system of the GI tract
Modulates immune responses through cytokines and chemokines in tissues distal from the gut
Boosting immune responsiveness
Maintaining everyday health in children and adults
May reduce risk of respiratory allergy and asthma later in life
A gastrointestinal flora in balance contributes to and promotes a better general health.
Limosilactobacillus reuteri Protectis has been shown to maintain digestive health and function and to keep the body’s natural defence.
1 chewable tablet or 5 drops daily
Weizman Z, Asli G, Alsheikh A. (2005) Pediatrics 115:5-9.
Health protection with BioGaia Protectis in children.
L. reuteri significantly reduced
Occurrence of number of febrile episodes and episodes of gastrointestinal infections were statistically less frequent in the probiotic group
L. reuteri (BioGaia) had a significantly superior effect compared to B. lactis
Significantly fewer doctor visits, fewer use of antibiotics and fewer absent days from day care
Prospective, randomized, placebo controlled study
201 healthy children, aged 4–10 months, were studied for 12 weeks in three different groups:
They were given formula with L. reuteri ATCC 55730 (BioGaia) or Bifidobacterium lactis Bb-12, or formula without probiotics (control)
Reduced sick days at home with short term
gastro-intestinal or respiratory illness
The frequency of sick days of ordinary workdays was 0.9% in the placebo group vs. 0.4% in the L. reuteri group (p<0.01)
L. reuteri: <1 sick day /individual and year
Placebo: 3 sick days /individual and year
Daily supplementation with the probiotic Limosilactobacillus reuteri ATCC 55730 (BioGaia) could reduce the incidence of common infections and thereby reduce short-term sick leave at a major Swedish workplace.
Effect pronounced in shift workers